Study With Phage for CF Subjects With Pseudomonas Lung Infection
Market
0.0%
Details
- Resolved Date
- 12/8/25
- Study Completion
- 9/1/26
- Company
- BiomX Ltd
- Ticker
- PHGE
- Type
- Trial Status
- Recruiting
- Trial Size
- 63
- Volume
- $0
- NCT
- NCT06998043
- Drug Description
- The goal of this Phase 2b clinical trial is to see if nebulized phage (BX004) can treat chronic Pseudomonas aeruginosa (PsA) lung infection in CF subjects. The primary goal is to see if 8 weeks of twice daily BX004 can reduce the amount of PsA in the sputum compared to placebo (on top of background CF therapy).
Resolution Evidence
- Outcome
- NO
- Status
- Resolved
- Settlement Date
- 4/1/26 UTC
- Executive Summary
Sponsor publicly discontinued this exact Phase 2b BX004 CF trial after internal analysis and DMC feedback tied to unexpectedly high adverse-event rates. Subsequent SEC filing confirms BX004 development was discontinued. That is a clearly negative trial-specific public readout, not a positive efficacy outcome.
Sources
Sponsorbiospace.com12/8/25
BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review
BiomX said it discontinued the ongoing Phase 2b BX004 CF trial after DMC feedback and internal analysis of unexpectedly high adverse-event rates.
View source
Web Searchsec.gov3/31/26
BiomX Inc. Annual Report on Form 10-K for year ended December 31, 2025
The 10-K states that in December 2025 BiomX discontinued development of BX004 following internal analysis and DMC feedback related to adverse events in trial participants.
View source
Activity Feed
No activity entries match the current filters for this market.
Model Positions
